Recombinant Canine GM-CSF Protein Summary
Product Specifications
Ala18-Lys144
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
1546-GM
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
Reconstitution | Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
1546-GM/CF
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: GM-CSF
GM-CSF was initially characterized as a factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3 - 5). It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled alpha -helices (8 - 10). Mature canine GM-CSF shares 49% - 57% amino acid sequence identity with mouse and rat GM-CSF and 69% - 72% with feline, human, and porcine GM-CSF. GM-CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF R alpha /CD116 and the signal transducing common beta chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 (11, 12). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF R alpha (13). The activity of GM-CSF is species specific between human and mouse, although human GM-CSF is active on canine cells (14, 15).
- Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
- Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509.
- Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163.
- Cao, Y. (2007) J. Clin. Invest. 117:2362.
- Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.
- Heuser, M. et al. (2007) Semin. Hematol. 44:148.
- Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321.
- Kaushansky, K. et al. (1992) Biochemistry 31:1881.
- Diederichs, K. et al. (1991) Science 254:1779.
- Nash, R.A. et al. (1991) Blood 78:930.
- Onetto-Pothier, N. et al. (1990) Blood 75:59.
- Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. USA 87:9655.
- Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483.
- Shanafelt, A.B. et al. (1991) J. Biol. Chem. 266:13804.
- Hogge, G.S. et al. (1990) Cancer Gene Ther. 6:26.
Citations for Recombinant Canine GM-CSF Protein
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
10
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Evaluation of the Efficacy of the Brucella canis RM6/66 deltavjbR Vaccine Candidate for Protection against B. canis Infection in Mice
Authors: LW Stranahan, SP Chaki, DG Garcia-Gon, OH Khalaf, AM Arenas-Gam
mSphere, 2020-05-20;5(3):.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay -
Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma
Authors: V Konduri, MM Halpert, YC Baig, R Coronado, JR Rodgers, JM Levitt, B Cerroni, S Piscoya, N Wilson, L DiBernardi, Z Omarbekov, L Seelhoff, V Ravi, L Douglass, WK Decker
Cancer Gene Ther., 2019-01-23;0(0):.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay -
Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy
Authors: AJ Hernández-, MA Franco-Mol, EE Coronado-C, P Zapata-Ben, EM Gamboa, Y Ramos-Zaya, SE Santana-Kr, C Rodríguez-
Res. Vet. Sci., 2018-10-05;121(0):23-30.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay -
Morphologic, phenotypic, and transcriptomic characterization of classically and alternatively activated canine blood-derived macrophages in vitro
Authors: F Heinrich, A Lehmbecker, BB Raddatz, K Kegler, A Tipold, VM Stein, A Kalkuhl, U Deschl, W Baumgärtne, R Ulrich, I Spitzbarth
PLoS ONE, 2017-08-17;12(8):e0183572.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay -
In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A
PLoS ONE, 2016-11-11;11(11):e0165477.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay -
Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.
Authors: Bauer TR, Olson EM, Huo Y
Gene Ther., 2011-01-13;18(6):553-9.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay -
Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.
Authors: Xiong W, Candolfi M, Liu C
PLoS ONE, 2010-06-11;5(6):e11074.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay -
Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model.
Authors: Lange S, Altmann S, Brandt B, Adam C, Riebau F, Vogel H, Weirich V, Hilgendorf I, Storb R, Freund M, Junghanss C
Exp. Hematol., 2009-01-01;37(1):143-50.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay -
Preventive and therapeutic effects of gene therapy using silica nanoparticles-binding of GM-CSF gene on white blood cell production in dogs with leukopenia.
Authors: Choi EW, Koo HC, Shin IS, Chae YJ, Lee JH, Han SM, Lee SJ, Bhang DH, Park YH, Lee CW, Youn HY
Exp. Hematol., 2008-06-11;36(9):1091-7.
Species: Canine
Sample Types: N/A, Serum
Applications: ELISA (Capture), ELISA (Standard) -
Effects of GM-CSF gene transfer using silica-nanoparticles as a vehicle on white blood cell production in dogs.
Authors: Choi EW, Shin IS, Chae YJ, Koo HC, Lee JH, Chung TH, Park YH, Kim DY, Hwang CY, Lee CW, Youn HY
Exp. Hematol., 2008-04-02;36(7):807-15.
Applications: ELISA (Standard)
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Canine GM-CSF Protein
There are currently no reviews for this product. Be the first to review Recombinant Canine GM-CSF Protein and earn rewards!
Have you used Recombinant Canine GM-CSF Protein?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image